In May 2024, Elevai established two wholly owned subsidiaries—Elevai Biosciences, Inc., and Elevai Skincare, Inc.—transitioning its commercialized exosome skincare brand into Elevai Skincare to enhance focus and market penetration. The company's lead biopharmaceutical asset, EL-22, leverages a first-in-class engineered probiotic approach to address obesity while preserving muscle during weight loss treatments, including GLP-1 receptor agonists.
Cyborg Score Rationale
Elevai went public in November 2023 with notable traction in the medical aesthetics skincare market backed by proprietary stem cell exosome technology. However, the company faced regulatory compliance challenges, withdrawing an exchange offer in November 2024 while working to regain Nasdaq listing compliance. The dual focus on commercialized skincare and early-stage biopharmaceutical development creates both opportunity and execution risk.
Top Insights
Over 300 leading clinics are integrating Elevai's regenerative products into their treatment protocols.
In August 2024, the company announced completion of a clinical study showing Elevai Enfinity to be safe and tolerable with significant improvements in skin appearance across multiple metrics.
Elevai signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio Inc., granting access to proprietary EMx technology to expand manufacturing capabilities and product portfolio.
In November 2024, the company withdrew an exchange offer to prioritize regaining compliance with Nasdaq's listing requirements due to SEC comments and unforeseen circumstances.
Named Competitors
Obagi — Physician-dispensed professional skincare systems
SkinMedica — Medical aesthetics skincare portfolio
Mounjaro — GLP-1 receptor agonist for obesity and metabolic health
Recent Developments
(May 2024) Established two wholly owned subsidiaries: Elevai Biosciences and Elevai Skincare, with restructured leadership
(August 2024) Announced positive clinical study results for Elevai Enfinity topical exosome serum showing improved skin appearance
(November 2024) Withdrew exchange offer and focused on regaining Nasdaq listing compliance
Open the full interactive Elevai Labs Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.